ORX Stock Overview
A specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Orexo AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 14.20 |
52 Week High | SEK 23.30 |
52 Week Low | SEK 13.32 |
Beta | 0.61 |
11 Month Change | -31.73% |
3 Month Change | -26.04% |
1 Year Change | -20.31% |
33 Year Change | -60.77% |
5 Year Change | -77.81% |
Change since IPO | -84.22% |
Recent News & Updates
Orexo AB (publ) (STO:ORX) Might Not Be As Mispriced As It Looks After Plunging 28%
Aug 02Orexo AB (publ) (STO:ORX) Just Reported Earnings, And Analysts Cut Their Target Price
Jul 20Recent updates
Orexo AB (publ) (STO:ORX) Might Not Be As Mispriced As It Looks After Plunging 28%
Aug 02Orexo AB (publ) (STO:ORX) Just Reported Earnings, And Analysts Cut Their Target Price
Jul 20Orexo AB (publ) (STO:ORX) Soars 28% But It's A Story Of Risk Vs Reward
May 29Orexo AB (publ)'s (STO:ORX) Business And Shares Still Trailing The Industry
Apr 03We Think Orexo (STO:ORX) Has A Fair Chunk Of Debt
Dec 09Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 24% Below Its Share Price
Jun 14Is Orexo (STO:ORX) A Risky Investment?
Apr 27Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 92% Above Its Share Price
Oct 19Would Orexo (STO:ORX) Be Better Off With Less Debt?
Sep 09Are Investors Undervaluing Orexo AB (publ) (STO:ORX) By 47%?
May 26Is Orexo (STO:ORX) Using Too Much Debt?
Apr 16Orexo (STO:ORX) Has Debt But No Earnings; Should You Worry?
May 04Shareholder Returns
ORX | SE Pharmaceuticals | SE Market | |
---|---|---|---|
7D | -11.7% | -5.3% | -6.7% |
1Y | -20.3% | 70.7% | 9.9% |
Return vs Industry: ORX underperformed the Swedish Pharmaceuticals industry which returned 70.7% over the past year.
Return vs Market: ORX underperformed the Swedish Market which returned 9.9% over the past year.
Price Volatility
ORX volatility | |
---|---|
ORX Average Weekly Movement | 8.4% |
Pharmaceuticals Industry Average Movement | 10.9% |
Market Average Movement | 5.9% |
10% most volatile stocks in SE Market | 12.2% |
10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: ORX's share price has been volatile over the past 3 months.
Volatility Over Time: ORX's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | 112 | Nikolaj Sorensen | www.orexo.com |
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis.
Orexo AB (publ) Fundamentals Summary
ORX fundamental statistics | |
---|---|
Market cap | SEK 489.96m |
Earnings (TTM) | -SEK 96.60m |
Revenue (TTM) | SEK 615.20m |
0.8x
P/S Ratio-5.1x
P/E RatioIs ORX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ORX income statement (TTM) | |
---|---|
Revenue | SEK 615.20m |
Cost of Revenue | SEK 72.50m |
Gross Profit | SEK 542.70m |
Other Expenses | SEK 639.30m |
Earnings | -SEK 96.60m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 24, 2024
Earnings per share (EPS) | -2.80 |
Gross Margin | 88.22% |
Net Profit Margin | -15.70% |
Debt/Equity Ratio | 1,894.6% |
How did ORX perform over the long term?
See historical performance and comparison